{"product_id":"cgtx-vrio-analysis","title":"Cognition Therapeutics, Inc. (CGTX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Cognition Therapeutics, Inc. (CGTX) truly positioned for long-term dominance, or are its current successes built on fragile foundations? We cut straight to the core of its competitive edge by dissecting its resources through the rigorous VRIO framework - Value, Rarity, Inimitability, and Organization. Uncover the distilled summary of our findings in \u0026amp;O4\u0026amp; below, and see exactly what makes Cognition Therapeutics, Inc. (CGTX) sustainably superior (or where it needs to adapt) before you read the full analysis.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e1. Zervimesine (CT1812) Phase 2 Clinical Data Package\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset for Cognition Therapeutics, Inc. (CGTX), and the data package is showing some compelling signals that justify the next, expensive steps in development.\u003c\/p\u003e\n\u003cp\u003eThe value here isn't abstract; it's quantified by clinical performance against a tough benchmark. If onboarding takes 14+ days, churn risk rises, but here, the data is the key to unlocking the next round of financing.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eKey Supporting Data (2025 Fiscal Context)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e95%\u003c\/strong\u003e slowing of cognitive decline (ADAS-Cog11) in the p-Tau217 low subgroup (SHINE AD study). \u003cstrong\u003e82%\u003c\/strong\u003e slowing in total NPI score (SHIMMER DLB study).\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eSpecific profile across AD and DLB as a sigma-2 receptor modulator is somewhat unique, though other AD programs exist.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eLow\u003c\/td\u003e\n    \u003ctd\u003eThe historical trial results are fixed; replicating the specific patient response profile and biomarker correlation is hard for competitors.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eFDA alignment on a registrational path. Completed a \u003cstrong\u003e$30 million\u003c\/strong\u003e registered direct offering. Cash runway estimated into Q2 2027.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eStrong Phase 2 data supports advancement, but sustained advantage requires successful completion of the two planned six-month Phase 3 studies.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis data package is the engine for the company right now. The $39.8 million in cash and equivalents as of September 30, 2025, plus $36.3 million in remaining grant funds, is being deployed to execute the Phase 3 plan based on these Phase 2 outcomes.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the organization's readiness:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA accepted registrational path based on two six-month Phase 3 trials.\u003c\/li\u003e\n\u003cli\u003ePhase 2 START study for early AD is over \u003cstrong\u003e75%\u003c\/strong\u003e enrolled.\u003c\/li\u003e\n\u003cli\u003eZervimesine could be the only disease-modifying therapy for DLB upon approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the execution risk of the upcoming Phase 3 trials; the 95% slowing was in a pre-selected subgroup, so the broader Phase 3 population might show less dramatic results. Still, the DLB data showing a 91% decline slowing in attention fluctuations is a powerful signal.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e2. FDA Alignment on Registrational Path (Alzheimer's Disease)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e De-risks the most critical development step by securing agreement with the FDA on a path to approval for Zervimesine in AD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Achieving this alignment, especially with biomarker enrichment, is a significant regulatory hurdle cleared.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is a specific, non-transferable regulatory achievement based on prior data submissions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The management team successfully navigated the end-of-Phase 2 meeting in July 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This regulatory milestone provides a clear, agreed-upon roadmap that competitors must now follow or argue against.\u003c\/p\u003e\n\u003cp\u003eThe FDA alignment confirmed that the proposed Phase 3 program may support a New Drug Application (NDA) filing for zervimesine.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe registrational path is supported by the FDA's view that two six-month Phase 3 studies could support an NDA filing.\u003c\/li\u003e\n\u003cli\u003eThe Phase 3 program is expected to enroll adults with mild-to-moderate Alzheimer's disease who have lower levels of p-tau217 at screening.\u003c\/li\u003e\n\u003cli\u003ePrevious clinical experience showed zervimesine arrested cognitive deterioration by 95% compared to placebo in this enriched population.\u003c\/li\u003e\n\u003cli\u003eThe Phase 2 'SHINE' study enrolled 153 adults with mild-to-moderate Alzheimer's disease.\u003c\/li\u003e\n\u003cli\u003eThe SHINE study was supported by approximately $30 million in National Institute on Aging grants.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eValue\/Dose\u003c\/th\u003e\n\u003cth\u003eStudy\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Study Duration (per study)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSix months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTo support NDA filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 Enrollment Criteria\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLower levels of p-tau217\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnrichment strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCognitive Decline Slowing (Enriched Subgroup)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 2 SHINE study vs. placebo (ADAS-Cog11)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Cognitive Slowing (mITT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 2 SHINE study vs. placebo (p-value: \u003cstrong\u003e0.310\u003c\/strong\u003e at week 26)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Dosing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100 mg\u003c\/strong\u003e or \u003cstrong\u003e300 mg\u003c\/strong\u003e orally daily\u003c\/td\u003e\n\u003ctd\u003ePhase 2 SHINE study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown from \u003cstrong\u003e$11.4 million\u003c\/strong\u003e in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding Secured\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRegistered direct offering completed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe management team's successful navigation of the July 9, 2025 end-of-Phase 2 meeting resulted in the alignment. The company has operational funding into Q2 2026.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e3. Sigma-2 Receptor Modulator Platform\/MoA\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMechanism: Orally delivered small molecule oligomer antagonist that penetrates the blood-brain barrier and selectively binds to the sigma-2 ($\\sigma$-2) receptor complex, displacing toxic A$\\beta$ or $\\alpha$-synuclein oligomers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eFunctional distinction from amyloid-clearing approaches.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSpecific small-molecule approach targeting $\\sigma$-2 receptor for this indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eClinical data points from Phase 2 trials:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSHINE (AD): 39% slowing of decline compared to placebo on the ADAS-Cog 11 scale after six months of treatment (pooled 100mg and 300mg doses) in $N=153$ participants.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSHINE (AD): For participants with baseline p-tau217 below the median, a 95% slowing of cognitive decline on ADAS-Cog11 was observed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSHIMMER (DLB): Up to 91% slowing compared to placebo across measures of behavior, function, cognition and movement after six months of treatment in $N=130$ patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSHIMMER (DLB): 82% less worsening on the Neuropsychiatric Inventory.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePlatform data summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial\/Metric\u003c\/td\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003ePatient $N$\u003c\/td\u003e\n\u003ctd\u003eTreatment Duration\u003c\/td\u003e\n\u003ctd\u003eKey Efficacy Number\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHINE\u003c\/td\u003e\n\u003ctd\u003eMild-to-Moderate Alzheimer's Disease\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e153\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix Months\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e39%\u003c\/strong\u003e slowing of decline on ADAS-Cog 11 vs placebo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHIMMER\u003c\/td\u003e\n\u003ctd\u003eMild-to-Moderate Dementia with Lewy Bodies\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e130\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix Months\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e91%\u003c\/strong\u003e slowing compared to placebo across measures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eUS Patent No. 9,796,672 provides composition of matter protection for CT1812 in the US through 2034.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePlatform underpins current and preclinical programs including Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eResearch and development expenses for the year ended December 31, 2024, were $41.7 million.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCash and cash equivalents as of December 31, 2024, were approximately $25.0 million, with total obligated grant funds remaining from the NIA of $50.0 million.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePlatform potential is contingent on successful progression through late-stage clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e4. Non-Dilutive NIH Grant Funding Stream\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvides significant, non-dilutive capital, reducing reliance on equity markets for early-stage costs. Total obligated grant funds remaining from the National Institute of Aging were \u003cstrong\u003e$41.9 million\u003c\/strong\u003e as of June 30, 2025. Cumulative grants since inception have totaled over \u003cstrong\u003e$171 million\u003c\/strong\u003e as of December 31, 2023.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrant Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemaining Obligated Grant Funds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative NIH Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$171 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSTART AD Trial NIA Grant\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$81 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunding for Phase 2 Alzheimer's trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDLB Study NIA Grant\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAwarded grant for Dementia with Lewy Bodies study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. NIH funding is competitive, but this level of sustained support is notable, including the \u003cstrong\u003e$81 million\u003c\/strong\u003e grant for the START AD trial.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. This funding is based on past scientific rigor and past success in winning competitive grants, evidenced by multiple awards such as the \u003cstrong\u003e$30 million\u003c\/strong\u003e grant for the DLB study.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. The company has a proven track record of securing and managing these funds, demonstrated by the successful management of the cumulative funding stream.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecured a \u003cstrong\u003e$1.6 million\u003c\/strong\u003e grant for hAME studies.\u003c\/li\u003e\n\u003cli\u003eReceived \u003cstrong\u003e$13.6 million\u003c\/strong\u003e to supplement the ongoing SHINE Phase 2 study.\u003c\/li\u003e\n\u003cli\u003eReported two multi-year grants totaling \u003cstrong\u003e$6.6 million\u003c\/strong\u003e in 2018.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. The remaining funds, combined with cash, provide an estimated runway into \u003cstrong\u003eQ2 2026\u003c\/strong\u003e, but the stream itself is finite.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e5. Financial Runway into Q2 2027\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The current financial position provides operational stability, allowing time to execute critical Phase 3 planning for zervimesine without immediate cash crunch pressure. Cash, cash equivalents, and restricted cash equivalents as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, were approximately \u003cstrong\u003e\\$39.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. A runway extending into the \u003cstrong\u003esecond quarter of 2027\u003c\/strong\u003e is considered favorable for a clinical-stage firm, especially when combined with non-dilutive funding sources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This metric is primarily a function of recent capital market activity, specifically the closing of the \u003cstrong\u003e\\$30 million\u003c\/strong\u003e registered direct offering, and disciplined expense management, rather than an inimitable internal asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management has clearly articulated a funding plan, supported by recent financing and grant awards, extending well into \u003cstrong\u003eQ2 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage is time-based, directly linked to the cash balance, and shrinks by the quarterly cash burn rate.\u003c\/p\u003e\n\u003cp\u003eThe financial strength is underpinned by both equity financing and substantial non-dilutive grant funding:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003e\\$30 million\u003c\/strong\u003e registered direct offering closed in September 2025, involving the sale of \u003cstrong\u003e14,700,000 shares\u003c\/strong\u003e at \u003cstrong\u003e\\$2.05 per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal obligated grant funds remaining from the National Institute of Aging (NIA) as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, were \u003cstrong\u003e\\$36.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey financial metrics from the Third Quarter 2025 provide context for the burn rate supporting the runway estimate:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (Q3 Ended Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eComparison Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$39.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$11.6 million (as of June 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Obligated Grant Funds Remaining (NIA)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$36.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$41.9 million (as of June 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$9.9 million (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$11.4 million (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$2.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$3.1 million (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's cash burn over the last year was reported at approximately \u003cstrong\u003e\\$30 million\u003c\/strong\u003e, which directly informs the runway projection.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e6. Biomarker-Enriched Phase 3 Strategy (p-tau217)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focuses expensive Phase 3 trials on a patient subgroup (lower plasma p-tau217) that showed a 95% slowing of cognitive decline in Phase 2, potentially boosting statistical power and success probability.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eStatistical Data from Phase 2 SHINE Subgroup Analysis\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMeasure\u003c\/th\u003e\n\u003cth\u003eCT1812 Treated (Lower p-tau217, n=69)\u003c\/th\u003e\n\u003cth\u003ePlacebo (Lower p-tau217, n=69)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eADAS-Cog 11 Slowing vs Placebo\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecline experienced\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMMSE Slowing vs Placebo\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e108%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecline experienced\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Duration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Baseline p-tau217\u003c\/td\u003e\n\u003ctd\u003eBelow 1.0pg\/mL\u003c\/td\u003e\n\u003ctd\u003eBelow 1.0pg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This specific, FDA-agreed enrichment strategy is cutting-edge for AD trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. It relies on proprietary analysis of Phase 2 data and specific regulatory buy-in.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The entire registrational plan presented at CTAD hinges on this design.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003ePhase 3 Registrational Plan Elements\u003c\/h\u003e\u003c\/h\u003e\n\u003cul\u003e\n\u003cli\u003eNumber of Studies: Two six-month, randomized 1:1 trials.\u003c\/li\u003e\n\u003cli\u003eDosing: 100 mg of oral zervimesine daily versus placebo.\u003c\/li\u003e\n\u003cli\u003eEfficacy Endpoint: iADRS composite scale.\u003c\/li\u003e\n\u003cli\u003eRegulatory Alignment: Strategy endorsed by the U.S. Food and Drug Administration (FDA) following a July 2025 end-of-Phase 2 meeting.\u003c\/li\u003e\n\u003cli\u003eFinancial Context: Phase 2 SHINE study was supported by approximately $30 million in National Institute on Aging (NIA) grant funds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. If successful, this targeted approach could become a standard for future AD drug development.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e7. Advanced Dementia with Lewy Bodies (DLB) Program\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCT1812 addresses the unmet need in DLB, which impacts about \u003cstrong\u003e1.4 million people in the U.S.\u003c\/strong\u003e and is considered the \u003cstrong\u003ecostliest form of dementia\u003c\/strong\u003e. Currently, \u003cstrong\u003eno disease-modifying therapeutics are approved for DLB\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2 SHIMMER study results demonstrated improvements across multiple measures:\u003c\/li\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e82%\u003c\/strong\u003e slowing of the total Neuropsychiatric Inventory (NPI).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e91%\u003c\/strong\u003e reduction in cognitive fluctuations (per CAF scale).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e52%\u003c\/strong\u003e preservation of functional ability (per ADCS-ADL scores).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e62%\u003c\/strong\u003e maintenance of motor function (per MDS-UPDRS Part III).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFew, if any, competitors have a small molecule this far along in DLB development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company has progressed beyond early-stage development, having completed the Phase 2 SHIMMER study and initiated an Expanded Access Program (EAP).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram\/Study Component\u003c\/td\u003e\n\u003ctd\u003eMetric\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 SHIMMER Study Enrollment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e130 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Treatment Duration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSix months\u003c\/strong\u003e (\u003cstrong\u003e24 weeks\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Dosing Arms\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100 mg CT1812\u003c\/strong\u003e, \u003cstrong\u003e300 mg CT1812\u003c\/strong\u003e, or placebo (randomized \u003cstrong\u003e1:1:1\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpanded Access Program (EAP) Enrollment Speed\u003c\/td\u003e\n\u003ctd\u003eReached full enrollment in \u003cstrong\u003ethree months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEAP Initial Participant Target\u003c\/td\u003e\n\u003ctd\u003eAround \u003cstrong\u003e30 individuals\u003c\/strong\u003e initially\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEAP Dosing Regimen\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100 mg\u003c\/strong\u003e of oral zervimesine \u003cstrong\u003edaily for up to one year\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe team is actively managing the EAP and using Phase 2 data to design a pivotal trial, evidenced by regulatory engagement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has scheduled a Type C meeting with the FDA for the \u003cstrong\u003esecond half of January\u003c\/strong\u003e to discuss the proposed Phase 3 program design for DLB.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, Cash and cash equivalents were approximately \u003cstrong\u003e$11.6 million\u003c\/strong\u003e, with an estimate of sufficient cash to fund operations into the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$6.7 million\u003c\/strong\u003e for the quarter ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's market capitalization was reported as \u003cstrong\u003e$142 million\u003c\/strong\u003e as of December 3, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. First-mover advantage in a major indication, if successful, is very hard to overcome.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e8. Oral Small Molecule Formulation\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eZervimesine (CT1812) is an experimental, \u003cstrong\u003eorally delivered\u003c\/strong\u003e small molecule oligomer antagonist that penetrates the blood-brain barrier. This oral formulation offers significant advantages in patient convenience and adherence over intravenous infusion methods common in CNS\/neurodegenerative treatment. For example, in the Phase 2 SHIMMER study for DLB, patients received one of two \u003cstrong\u003eoral doses\u003c\/strong\u003e daily for \u003cstrong\u003esix months\u003c\/strong\u003e. The expanded access program for DLB provides daily \u003cstrong\u003e100 mg oral doses\u003c\/strong\u003e for up to \u003cstrong\u003eone year\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFeature\u003c\/td\u003e\n\u003ctd\u003eOral CT1812 (Zervimesine)\u003c\/td\u003e\n\u003ctd\u003eTypical CNS Infusion Therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministration Route\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOral\u003c\/strong\u003e administration\u003c\/td\u003e\n\u003ctd\u003eIntravenous (IV) infusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Frequency (Clinical)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOnce daily\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVaries, often less frequent than daily, requires clinical setting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Range in SHINE Trial (AD)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100 mg\u003c\/strong\u003e or \u003cstrong\u003e300 mg\u003c\/strong\u003e daily\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHINE Trial Duration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e182 days\u003c\/strong\u003e (\u003cstrong\u003e6 months\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhile many new drugs are oral, for a CNS\/neurodegenerative target, an orally available small molecule that penetrates the blood-brain barrier is a strong feature. The SHINE trial randomized \u003cstrong\u003e153\u003c\/strong\u003e adults with mild to moderate Alzheimer's disease to receive one of two \u003cstrong\u003eoral doses\u003c\/strong\u003e or placebo.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCompetitors may have oral candidates, but CT1812’s specific profile as a selective sigma-2 ($\\sigma$-2) receptor modulator is unique. Preclinical work showed CT1812 compounds could occupy up to \u003cstrong\u003e80 percent\u003c\/strong\u003e of sigma2 receptors in mouse models. The Phase 2 SHINE trial showed a \u003cstrong\u003e39%\u003c\/strong\u003e slowing of cognitive decline favoring CT1812 over placebo on the ADAS-Cog 11 scale in the pooled dose group (a \u003cstrong\u003e1.04-point\u003c\/strong\u003e difference).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe oral nature is a key selling point in all development discussions, supported by the company’s financial structure and focus. As of September 30, 2025, the company had approximately \u003cstrong\u003e$39.8 million\u003c\/strong\u003e in cash and \u003cstrong\u003e$36.3 million\u003c\/strong\u003e in obligated grant funds remaining from the National Institute of Aging. The company estimated sufficient cash to fund operations into the \u003cstrong\u003esecond quarter of 2027\u003c\/strong\u003e. Research and development expenses for Q3 2025 were \u003cstrong\u003e$3.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe oral administration supports a lower patient burden, which is a factor in commercial viability. The company was valued at \u003cstrong\u003e$142 million\u003c\/strong\u003e as of December 3, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. The oral formulation aids commercialization prospects by reducing patient burden compared to infusions. The company CEO stated results were comparable in magnitude to currently approved antibodies with \u003cstrong\u003egreat ease of administration as a once daily dose\u003c\/strong\u003e. The SHIMMER DLB trial enrolled \u003cstrong\u003e130\u003c\/strong\u003e patients.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOral CT1812 showed a \u003cstrong\u003e95%\u003c\/strong\u003e slowing in cognitive decline versus placebo in a prespecified subgroup of SHINE participants (n=\u003cstrong\u003e45\u003c\/strong\u003e vs n=\u003cstrong\u003e24\u003c\/strong\u003e) as assessed by ADAS-Cog11 at week \u003cstrong\u003e26\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn the DLB SHIMMER study, patients treated with CT1812 for \u003cstrong\u003esix months\u003c\/strong\u003e experienced improvement across behavioral, functional, cognitive, and movement measures compared to placebo.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCognition Therapeutics, Inc. (CGTX) - VRIO Analysis: \u003cstrong\u003e9. Leadership and Regulatory Navigation Expertise\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability of leadership, like CEO \u003cstrong\u003eLisa Ricciardi\u003c\/strong\u003e, to secure key regulatory milestones, such as the \u003cstrong\u003eFDA alignment\u003c\/strong\u003e on a registrational path for zervimesine following the end-of-Phase 2 meeting on \u003cstrong\u003eJuly 9, 2025\u003c\/strong\u003e, is crucial for capital efficiency.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Experienced biotech leadership is common, but successfully navigating complex neurodegenerative pathways is less so.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is tied to the specific relationships and communication styles developed over time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The CEO directly links this capability to the company’s ability to attract funding. Cognition Therapeutics presented the Phase 3 registrational plan for zervimesine at \u003cstrong\u003eCTAD on Dec 1, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Depends on the tenure and continued effectiveness of the current executive team.\u003c\/p\u003e\n\n\u003cp\u003eThe Phase 3 plan, discussed with the \u003cstrong\u003eFDA\u003c\/strong\u003e, involves:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTwo randomized \u003cstrong\u003e1:1 six-month Phase 3 studies\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDosing of \u003cstrong\u003e100 mg\u003c\/strong\u003e of oral zervimesine daily.\u003c\/li\u003e\n\u003cli\u003eEnrichment for patients with lower plasma p-tau217 at screening.\u003c\/li\u003e\n\u003cli\u003eEfficacy measured by the \u003cstrong\u003eiADRS\u003c\/strong\u003e composite scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe company is actively evaluating resources across Alzheimer's disease and DLB programs. The following financial metrics provide context for capital planning, including the required Phase 3 budget estimate:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$153.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 1, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.74\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 1, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice Return (Past Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e332.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAccording to InvestingPro data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Restricted Cash\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$11.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Obligated Grant Funds Remaining (NIH)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom National Institute on Aging\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ2 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of August 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the quarter ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the quarter ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNegative EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$44.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent operational burn indicator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.44\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial health indicator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516134023317,"sku":"cgtx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cgtx-vrio-analysis.png?v=1740161524","url":"https:\/\/dcf-model.com\/products\/cgtx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}